CA2387819A1 - Sustained-release formulations for treating cns-mediated disorders - Google Patents
Sustained-release formulations for treating cns-mediated disorders Download PDFInfo
- Publication number
- CA2387819A1 CA2387819A1 CA002387819A CA2387819A CA2387819A1 CA 2387819 A1 CA2387819 A1 CA 2387819A1 CA 002387819 A CA002387819 A CA 002387819A CA 2387819 A CA2387819 A CA 2387819A CA 2387819 A1 CA2387819 A1 CA 2387819A1
- Authority
- CA
- Canada
- Prior art keywords
- active compound
- sustained
- release
- composition
- isovaleramide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16021099P | 1999-10-19 | 1999-10-19 | |
| US60/160,210 | 1999-10-19 | ||
| PCT/US2000/041267 WO2001028516A2 (en) | 1999-10-19 | 2000-10-19 | Sustained-release formulations for treating cns-mediated disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2387819A1 true CA2387819A1 (en) | 2001-04-26 |
Family
ID=22575965
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002387819A Abandoned CA2387819A1 (en) | 1999-10-19 | 2000-10-19 | Sustained-release formulations for treating cns-mediated disorders |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1225888A2 (de) |
| JP (1) | JP2003512311A (de) |
| CN (1) | CN1409630A (de) |
| AU (1) | AU780505B2 (de) |
| CA (1) | CA2387819A1 (de) |
| MX (1) | MXPA02003976A (de) |
| TW (1) | TWI252761B (de) |
| WO (1) | WO2001028516A2 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6589994B1 (en) | 1996-08-30 | 2003-07-08 | Nps Pharmaceuticals, Inc. | Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound |
| US8679533B2 (en) | 2002-07-25 | 2014-03-25 | Pharmacia Corporation | Pramipexole once-daily dosage form |
| US20060025477A1 (en) * | 2004-07-22 | 2006-02-02 | Artman Linda D | Analogs of isovaleramide, a pharmaceutical composition including the same, and a method of treating central nervous system conditions or diseases |
| KR101052436B1 (ko) * | 2004-08-13 | 2011-07-29 | 베링거 인겔하임 인터내셔날 게엠베하 | 프라미펙솔 또는 약제학적으로 허용되는 이의 염을함유하는 연장 방출형 정제 제형, 이의 제조방법 및 이의용도 |
| KR20070050081A (ko) | 2004-08-13 | 2007-05-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 프라미펙솔 또는 약제학적으로 허용되는 이의 염을포함하는 연장 방출형 펠렛 제형, 이의 제조방법 및 이의용도 |
| US20070134315A1 (en) * | 2005-12-08 | 2007-06-14 | Viera Michael L | Orally administrable extended release pellet and tablet formulations of a highly water soluble compound |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL128724A (en) * | 1996-08-30 | 2003-05-29 | Nps Pharma Inc | Pharmaceutical compositions containing isovaleric acid derivatives for treating various neurological pathologies |
-
2000
- 2000-10-19 CA CA002387819A patent/CA2387819A1/en not_active Abandoned
- 2000-10-19 WO PCT/US2000/041267 patent/WO2001028516A2/en active IP Right Grant
- 2000-10-19 CN CN00817059A patent/CN1409630A/zh active Pending
- 2000-10-19 JP JP2001531111A patent/JP2003512311A/ja active Pending
- 2000-10-19 AU AU19695/01A patent/AU780505B2/en not_active Ceased
- 2000-10-19 EP EP00982701A patent/EP1225888A2/de not_active Withdrawn
- 2000-10-19 MX MXPA02003976A patent/MXPA02003976A/es active IP Right Grant
-
2001
- 2001-04-11 TW TW090108635A patent/TWI252761B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001028516A3 (en) | 2002-02-21 |
| MXPA02003976A (es) | 2003-09-25 |
| EP1225888A2 (de) | 2002-07-31 |
| CN1409630A (zh) | 2003-04-09 |
| TWI252761B (en) | 2006-04-11 |
| JP2003512311A (ja) | 2003-04-02 |
| WO2001028516A2 (en) | 2001-04-26 |
| AU1969501A (en) | 2001-04-30 |
| AU780505B2 (en) | 2005-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100280099B1 (ko) | 방출 개시 제어 및 방출 속도 제어형 제제 | |
| ES2606463T3 (es) | Combinación de formas de dosificación de levodopa/carbidopa de liberación inmediata y liberación controlada | |
| EP2217217B1 (de) | Pharmazeutische zusammensetzungen von pregabalin mit kontrollierter freisetzung | |
| EP1940361B1 (de) | Pharmazeutische dosierformen mit sofortiger freisetzung und/oder kontrollierter freisetzung | |
| US6576260B2 (en) | Sustained-release form of administration containing tramadol saccharinate | |
| KR20160045728A (ko) | 디메틸푸마레이트를 포함하는 일일 저용량 투여용 약제학적 조성물 | |
| US20110135723A1 (en) | Pharmaceutical compositions containing pregabalin | |
| JP2015536956A (ja) | ヒドロモルホンおよびナロキソンを含む医薬組成物 | |
| JP2004521910A (ja) | トラマドール系薬剤 | |
| US11717501B2 (en) | Magnesium threonate compositions and uses thereof | |
| US20150164920A1 (en) | Controlled release formulation comprising mesalamine | |
| US7235258B1 (en) | Sustained-release formulations for treating CNS-mediated disorders | |
| AU780505B2 (en) | Sustained-release formulations for treating CNS-mediated disorders | |
| US20050220873A1 (en) | Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist | |
| BR112014013374B1 (pt) | Comprimidos de acamprosato e usos de acamprosato referência cruzada aos pedidos relacionados | |
| WO2004024128A2 (en) | Modified release ketoprofen dosage form | |
| US20210290557A1 (en) | Multi-particulate pharmaceutical composition, immediate release pellets, sustained release pellets, enteric release pellets and use thereof | |
| AU2005202728A1 (en) | Sustained-release formulations for treating CNS-mediated disorders | |
| US20050220874A1 (en) | Pharmaceutical dosage forms having immediate release and controlled release properties that contain a GABAB receptor agonist | |
| RU2292877C2 (ru) | Лекарственная ретард-форма, содержащая сахаринат трамадола | |
| US8962020B2 (en) | Long-acting and controlled release formulations of 2-[(3-chlorophenyl) amino] phenylacetic acid | |
| US20050220864A1 (en) | Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist | |
| KR20150123302A (ko) | 특정한 체외 용해 프로파일 또는 약리역학 파라미터를 갖는 도네페질의 약제학적 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |